A major federal shift in marijuana classification could reshape how cannabis and CBD businesses operate across Colorado, especially in the medical space. Business owners are already reacting, seeing potential changes in taxes, research access, and how products are developed and sold moving forward.
The change does not legalize marijuana nationwide, but it signals a different approach from federal regulators that many in the industry have been waiting for. In Colorado, where more than 50,000 patients remain registered, even small policy shifts can influence how businesses plan ahead.
What the Reclassification Means for the Industry
The federal shift moves marijuana from Schedule I to Schedule III, placing it alongside substances that have accepted medical use, such as medications containing codeine. For businesses in Colorado, that change matters because it signals a different legal and scientific footing moving forward.
Industry operators say one of the biggest impacts could come from expanded research. For years, strict classification limited what could be studied and how results were used. With this adjustment, researchers may gain more freedom to explore medical applications and long-term effects.
Federal officials describe this as an early step rather than a final decision, with a hearing set for June 29 to review broader changes. That timeline keeps uncertainty in place, but it also gives businesses time to prepare for potential regulatory shifts.
Business Opportunities and Tax Relief Potential
Business owners across Colorado see this shift as more than a policy update, they see practical room to grow. Jason Castellano said, “The reclassification of marijuana is going to open up a lot of opportunities for dispensaries,” pointing to expansion in products and operations.
For many operators, taxes remain the biggest pressure point, largely due to the IRS Section 280E, which prevents standard business deductions. Jason Castellano said, “I believe with the tax incentives and being able to write off certain business expenses that were otherwise not available,” pointing to relief businesses have been waiting for.
Entrepreneurs like Elvis Edwards are also watching closely as they plan next steps. “I’ve been waiting for this for a long time, for me it is the banking and new opportunities,” Edwards said, signaling interest in moving further into THC-based products.
Limits and Market Reality in Colorado
Even with new possibilities, the reality in Colorado shows a market that has been tightening for years. Medical marijuana participation has declined, with more than 50,000 registered patients statewide, while overall cannabis sales have dropped, affecting how businesses plan long-term growth.
In Denver, the shift is even clearer when looking at licensing numbers. Active medical marijuana store licenses fell from 152 in April 2022 to 83 in 2026. Eric Escudero said there is no path for new licenses, meaning businesses must acquire existing operations or look outside the city.
Brad Zasada said the benefits are uneven, noting, “It costs you a large portion of your revenues to operate, and you can't deduct much of it on your federal taxes,” emphasizing that medical focused businesses stand to gain the most from changes.
Endnote
Debate around this shift is already building as business owners weigh who actually benefits and how quickly changes take effect. Relief tied to IRS Section 280E could help medical operators, but in Denver only five dispensaries operate purely as medical, limiting immediate reach.
Federal officials continue to frame reclassification as an early step, with a June 29 hearing set to review broader changes affecting patients, researchers and businesses. What happens there may decide how far this shift goes, and whether expectations match reality across Colorado.